A new ADHD drug targets three brain chemicals instead of two. Here’s what that means
The Conversation
Centanafadine (Simtriyo) is a newly approved ADHD medication that uniquely targets three neurotransmitters—dopamine, noradrenaline, and serotonin—rather than just the two typically affected by existing stimulant drugs. By slowing the reuptake of all three chemicals, it offers a distinct treatment mechanism for adults and children aged six and older, addressing both core ADHD symptoms and potential mood or appetite regulation issues. This provides an alternative option for patients who may not respond to traditional dopamine-focused stimulants or non-stimulants like atomoxetine.
All articles from 13 August 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.